See our Mounjaro diet guide
We break this down fully in our R etatrutide diet post
Patient-specific factors that influence choice include: Concurrent diabetes : Patients with type 2 diabetes may have broader access through NHS prescribing pathways BMI and weight loss goals : Higher BMI patients may benefit from agents with greater weight loss efficacy Tolerability : Previous experience with gastrointestinal side effects may guide selection Injection preference : Some patients strongly prefer weekly over daily injections, or oral over injectable formulations Cardiovascular disease : Certain GLP-1 agonists have proven cardiovascular benefits, which may be relevant for high-risk patients Ultimately, the choice should be individualised through shared decision-making between patient and clinician, considering the available evidence, licensed indications, local prescribing policies, and patient preferences
Acharya NK, Levin EC, Clifford PM, Han M, Tourtellotte R, Chamberlain D, et al
Photo 2: "What B12-tinted semaglutide looks like." A 5 mL vial of B12-supplemented compounded semaglutide showing the characteristic ruby-red color